Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
about
The human ITPA polymorphic variant P32T is destabilized by the unpacking of the hydrophobic coreA disease spectrum for ITPA variation: advances in biochemical and clinical researchProgress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicityA novel approach for identifying causal models of complex diseases from family dataGenome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variantsRole of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-α-2a with ribavirin therapy: a case reportAssociation between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients.Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.The impact of rare and low-frequency genetic variants in common diseaseShortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trialErythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapyClinical utility of pharmacogenomics in the management of hepatitis C.Pharmacogenomics of antimicrobial agents.Genome-Wide Association Studies: "SNPing" Away at Liver Disease.Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypesRole of genetic polymorphisms in hepatitis C virus chronic infection.Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysisIL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis CITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionImpact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC StudyIs the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis CInfluence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection.Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.Host genetic variants in the pathogenesis of hepatitis C.PharmGKB summary: peginterferon-α pathway.Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C VirusIndividualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.Pharmacogenomics in pediatric leukemia.The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C.Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
P2860
Q27677053-1C49F5A7-8BA2-458E-88A4-DC02DA4A81D3Q28069352-2A932568-A2AA-4E7E-913A-A821A9E2EE3AQ28083100-F42F03FA-FEF0-4604-A434-02E2C8FC5EC1Q30896568-AAB0D1B9-1C57-416E-B369-1BDB1915EC12Q33395929-5AD4E913-3BDA-4429-8841-BCDE0EECE097Q33404251-F9F65D1A-ADBF-41B3-BF09-847D6A47D79BQ33408167-50B8728A-24BB-4456-9A17-B40ABB3FF43FQ33413883-00A70C6E-377C-44D6-9669-24DC17B85AF9Q33418008-F27D5C7B-8CBC-4264-B0E2-1245A3C9F580Q33429063-4AF4FFA5-3C9D-46ED-9B05-7AC7FED40DABQ33430028-C5DE4894-E744-4D1F-B052-BEAA1495BADEQ33613854-D2120C37-BE47-4A3D-AC92-ACEFC62ED155Q33945882-E5BE0ED5-8AC8-466B-B2F9-A7854902868AQ34246440-27B40F9C-9E59-4323-8A86-1099B3C99008Q34464613-FE3AAD53-919A-436B-8AAF-058ACAB58E44Q34977413-93E90B0B-F242-4F00-9CFB-7CA71FF998FDQ35151287-4C4EC496-BAA9-4000-959F-F66F39EB2FDEQ35156156-759DF534-AD37-4F15-9720-AE8EC92869D5Q35768047-758099A8-8055-4B41-8F3E-85FBC7EB2197Q35779058-B4EA630C-4111-419B-B4D5-FD70ED4FCBDAQ35799774-DCE42FF6-3AA0-4636-A699-F7457A7F7C61Q35838595-BB87979E-5C0E-482F-8D9A-A2978A869DAEQ35864362-B71500B0-30FE-4C1F-92DD-7043FBAF2D03Q35869247-71079E81-BECD-41C4-AD0F-C75EFE360FEFQ35947900-F5734F58-54B6-4F41-9477-4E607F31CC4BQ35975174-F05C0379-3311-436E-BB78-114BC51D4E70Q36018931-5D4BF7C6-3C6F-42DD-B188-F71E87A1BB9AQ36059685-8C6224AA-8D50-41EC-A265-BAAC38BBB397Q36070215-10E1F904-D10D-46BA-BCD4-CE2445F0DC38Q36378784-C4991FF0-B3E7-4D13-B71A-9C985A5C87A8Q36382719-3604AE8C-2F88-4D16-9520-DF13BFBE478AQ36457789-34894BB7-C9A9-4C81-87F6-5DA19D872FFEQ36482742-F356EFD3-FEB8-4BDA-9B58-E4DFB75CBD23Q36590755-7044C52D-F425-4BBE-97F1-C3F788E30913Q36600070-4D96765A-BFBA-4F89-A131-867079034108Q36699256-4F52AC66-CEDF-4932-89F9-9302E3CA8EBDQ36699265-068608F3-91AE-4FA4-862F-23CAECF78D8BQ36727952-45D081A4-CB64-42C1-91B9-12026E269805Q36853851-BA79027B-C21D-4D1F-AB33-32B2F3F87872Q36967047-6C21C22F-E887-42A7-B364-BCC2F05A8C4F
P2860
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Variants in the ITPA gene prot ...... d for ribavirin dose reduction
@ast
Variants in the ITPA gene prot ...... d for ribavirin dose reduction
@en
Variants in the ITPA gene prot ...... d for ribavirin dose reduction
@nl
type
label
Variants in the ITPA gene prot ...... d for ribavirin dose reduction
@ast
Variants in the ITPA gene prot ...... d for ribavirin dose reduction
@en
Variants in the ITPA gene prot ...... d for ribavirin dose reduction
@nl
prefLabel
Variants in the ITPA gene prot ...... d for ribavirin dose reduction
@ast
Variants in the ITPA gene prot ...... d for ribavirin dose reduction
@en
Variants in the ITPA gene prot ...... d for ribavirin dose reduction
@nl
P2093
P2860
P1433
P1476
Variants in the ITPA gene prot ...... d for ribavirin dose reduction
@en
P2093
Alexander J Thompson
Andrew J Muir
David B Goldstein
Dongliang Ge
Hans L Tillmann
John G McHutchison
Kevin V Shianna
Keyur Patel
Michael W Fried
Susanna Naggie
P2860
P304
P356
10.1053/J.GASTRO.2010.06.016
P407
P577
2010-06-12T00:00:00Z